enGene Holdings Inc. (NASDAQ:ENGNW – Get Free Report) saw a significant decline in short interest during the month of September. As of September 15th, there was short interest totaling 1,699 shares, a decline of 63.6% from the August 31st total of 4,663 shares. Based on an average trading volume of 7,009 shares, the days-to-cover ratio is currently 0.2 days.
enGene Trading Down 7.3%
Shares of ENGNW traded down $0.02 during mid-day trading on Tuesday, reaching $0.20. The company’s stock had a trading volume of 13,000 shares, compared to its average volume of 15,871. enGene has a 12-month low of $0.11 and a 12-month high of $4.20. The company’s 50 day moving average is $0.28 and its 200 day moving average is $0.83.
enGene Company Profile
enGene Inc is a clinical-stage biotechnology company developing non-viral gene therapies designed to treat diseases affecting mucosal tissues. The company’s proprietary DUAL (Decentralized Unit for Activated Loading) platform is intended to enable the local delivery of therapeutic DNA directly to target tissues, with the goal of producing treatment effects while limiting systemic exposure.
enGene’s lead investigational product is detalimogene voraplasmid, also known as EG-70, an intravesical gene therapy being developed for non-muscle-invasive bladder cancer.
Further Reading
- Five stocks we like better than enGene
- CarMax Just Gave Investors a Better Reason to Believe in the Turnaround
- CoreWeave Comes With Risks: Analysts Split on What Matters Most
- Bottlenecking the Future: TSMC Prices Out the Competition
- Fervo Energy Hits Geothermal Milestone: Will It Matter For The Stock?
Receive News & Ratings for enGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for enGene and related companies with MarketBeat.com's FREE daily email newsletter.
